![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer's disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Acumen Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022